ERG’s overexpression has been identified as a biomarker correlated with adverse AML clinical outcomes, and its deregulation (i.e., intragenic deletions) found in ALL patients, has been the result of favorable outcomes (70, 96–100, 243, 244). The gene discussed is ERG; the disease is acute myeloid leukemia.